Objective: To assess the effect of more intensive medical therapy on the rate of transcranial Doppler (TCD) microemboli and cardiovascular events in patients with asymptomatic carotid stenosis (ACS).
Conclusions: Cardiovascular events and microemboli on TCD have markedly declined with more intensive medical therapy. Less than 5% of patients with ACS now stand to benefit from revascularization; patients with ACS should receive intensive medical therapy and should only be considered for revascularization if they have microemboli on TCD.
Arch Neurol. 2010;67 (2) :180-186 P ATIENTS WITH ASYMPTOMATIC carotid stenosis (ACS) are at high risk of vascular disease, more so for myocardial infarction than for stroke. 1 Therefore, all patients with ACS warrant intensive medical therapy for atherosclerosis. Although clinical trials showed a statistically significant reduction of stroke with carotid endarterectomy in the past, 2 the absolute risk reduction was a modest 1% per year, with no benefit for women. 3 The resulting number needed to treat with endarterectomy to prevent 1 stroke in 2 years, 67 to 83, is thus very high. 4, 5 Furthermore, the benefit of surgery in clinical trials was predicated on less intensive medical therapy than is now prevalent and on a low surgical risk of stroke or death of only 3%, which is seldom duplicated in real-world practice. 6 To date, the literature does not support arterial stenting in asymptomatic patients, because it carries a risk of complications of approximately 5% to 12%. [7] [8] [9] The most recent results show that carotid stenting carries a higher risk than endarterectomy in symptomatic carotid stenosis [10] [11] [12] and ACS. 12 Recently, Abbott and colleagues 13, 14 have called for a halt to revascularization for ACS.
In1990,webegantomeasurecarotidtotal plaque area, defined as the sum of the crosssectional areas of all plaques measured in a longitudinal view in the common, internal, and external carotids on both sides. 15, 16 In 2002, we showed that total plaque area is a strong predictor of stroke, death, and myocardial infarction. Specifically, after adjusting for age, sex, cholesterol, systolic blood pressure, pack-years of smoking, diabetes, total homocysteine, and treatment of lipids and hypertension, we observed that patients in the top quartile of total plaque area had a 3.4 times higher riskofstroke,death,andmyocardialinfarctionduring5years. This finding has since been validated in the Tromsø Study. 17 Furthermore, patients with total plaque area progression in the first year despite treatment of traditional risk factors according to consensus guidelines had twice the risk of those events, even after adjustment for the same panel of risk factors. 16 This caused us to change the paradigm for patient treatment in our vascular clinics from treating risk factors to treating arteries. Therapy was intensified in patients with a high plaque burden and further intensified if the plaque was progressing despite achieving target levels of risk factors like blood pressure, smoking cessation, and low-density lipoprotein cholesterol. The explicit goal is to achieve plaque regression as opposed to merely attaining specified target levels of intermediate traits such as blood pressure or plasma lipoprotein profile.
Microemboli, as detected by transcranial Doppler (TCD) monitoring, were associated with increased risk of stroke among patients with symptomatic carotid stenosis, 18 and in a mixed population of patients with symptomatic and asymptomatic carotid stenosis. 19 In 2005 we reported 20 that among patients with ACS, TCD-detected microemboli were very useful in identifying patients who might be candidates for revascularization. Among the 90% of ACS patients who had no microemboli, the risk of stroke within 1 year was only 1% (95% confidence interval, 1.01-1.36). Patients with such a low risk would not stand to benefit from procedures, such as endarterectomy, which showed a real-world, 30-day risk of stroke or death of 4% to 7%, 6 or stenting, which showed stroke or death risks of approximately 5% to 12%. 8, 21 On the other hand, the 10% of patients with microemboli had a stroke risk in the first year of 15.6% (95% confidence interval, 4.1-79), suggesting that they might be more optimal candidates for revascularization.
Finally, during a study of biological differences among ACS patients, we found, to our frustration, that in the past few years we became less able to find sufficient numbers of patients with microemboli on TCD to achieve the planned statistical power. We had observed in our earlier study 20 that among those with emboli at baseline, they were present in only 34% of patients after 1 year and only 9% after 2 years, suggesting that microemboli decline with medical therapy. We therefore hypothesized that the incidence of microemboli was reduced in ACS patients because of more intensive medical therapy in recent years and that this reduced incidence was coincident with instituting more aggressive medical therapy, probably through stabilization of carotid plaques. We also hypothesized that more intensive medical therapy may have reduced the risk of patients with microemboli and that the predictive value of microemboli may therefore have been reduced by more intensive medical therapy. We report herein the investigations undertaken to test those hypotheses.
METHODS

CLINICAL POPULATIONS
The study population was recruited beginning in 2000 for a prospective peer-reviewed study funded by the Heart and Stroke Foundation of Ontario to investigate whether TCD microemboli predicted cardiovascular risk in ACS. Patients consented to a protocol approved by the University of Western Ontario ethics review board. The initial results of the study, in the first 319 patients, were published in 2005. 16 Patients were included in the study if they had ACS of at least 60%, defined by peak velocities that qualified patients in our laboratory for the Asymptomatic Carotid Artery Surgery trial. Approximately one-third of the patients had been referred to J.D.S. at the Stroke Prevention Clinic at University Hospital in London, Ontario, Canada, because they had ACS detected by the referring physician (usually a bruit led to carotid ultrasonography). Asymptomatic carotid stenosis was detected in the remainder of patients in the course of routine carotid Doppler ultrasonography examinations when they came for measurement of carotid plaque area or for visits to our Stroke Prevention Clinic or Atherosclerosis Prevention Clinic.
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PLAQUE MEASUREMENT
All patients underwent a baseline measurement of total plaque area, with serial follow-up measurements at approximately annual intervals, as previously described. 16 Briefly, all plaques seen in the common, internal, and external carotids on both sides of the body were measured by duplex sonography by 2 sonographers (M.D. and J.D.; both are very experienced in measurement of total plaque area; M.D. invented plaque area measurement in our laboratory in 1990). Plaque was measured with an ATL/Phillips HDI 5000 duplex scanner with compound imaging (SonoCT; Philips, Andover, Massachusetts). The cross-sectional area of each plaque was measured in a longitudinal view in the plane where the plaque area was greatest; the total of the crosssectional areas of all plaques was total plaque area. As previously reported, 16 the interobserver for plaque measurement was 0.85.
TRANSCRANIAL DOPPLER
The analyses presented in this article are based on the presence of microemboli at the baseline TCD study. All patients underwent a routine TCD study with a 2-MHz probe to identify intracranial stenosis. This was followed by monitoring of both middle cerebral arteries, preferably in the M1 segment, through a posterior or middle temporal window. Middle cerebral arteries were identified bilaterally within depths of insonation of 35 to 56 mm from the temporal window and monitored for up to 1 hour, using a head-fixation device. Because the headgear is somewhat uncomfortable and because some patients had difficulty lying still for long periods, monitoring was stopped after at least 40 minutes or if the test was positive (exhibiting Ͼ2 microemboli ipsilateral to the stenosed carotid artery). Two TCD machines were used to monitor patients: a Nicolet TC 4040 Pioneer for the first 150 patients and a PMD 100 (TCD 100 M) flow Trax Power M-Mode Doppler for the remainder. Microembolic signals were defined by unidirectionality, duration of shorter than 300 milliseconds, and intensity of more than 8 dB above the Doppler background, with adjustment of gain to enhance detection. The settings for microembolus detection were leading cols of 255 mm, trailing cols of 255 mm, a microemboli threshold of 9 mm, and rejection of 55 mm, corresponding to international consensus recommendations. 23 All sessions were recorded on the machine's hard drive for review and confirmation of microembolic signals noted during monitoring.
Intracranial stenosis was diagnosed if there was a stenosis of 50% or greater of a middle cerebral artery; this was defined by a peak systolic velocity of 150 cm /s, with a mean velocity of 100 cm /s in the absence of a generalized hyperdynamic state. Patients were categorized as having or not having intracranial stenosis.
EVENTS
Events were ascertained by a questionnaire at each annual visit, followed up by review of hospital records and/or contact with family physicians. The database was designed a priori to assess a composite end point of stroke, death, myocardial infarction, or carotid endarterectomy for development of symptomatic stenosis.
STATISTICAL ANALYSIS
Data were entered and analyzed in SPSS, version 16.0 (SPSS Inc, Chicago, Illinois). Analysis of variance was used to compare continuous variables across groups. The 2 and the Fisher exact tests were used to compare categorical variables across groups (microemboli positive vs negative; before vs after 2003). The log-rank test was used in Kaplan-Meier survival analyses. Binary logistic regression with conditional entry of covariates was used to adjust for age, sex, smoking, systolic blood pressure, cholesterol, and cholesterol to high-density lipoprotein ratio for comparisons of rates of microemboli and events across groups.
We analyzed the proportion of patients with ACS who had microemboli at their first TCD embolus detection test before and after 2003, by which time our change to more intensive medical therapy had been implemented. We also analyzed the event rate among patients with and without microemboli at baseline and analyzed the mean rate of plaque progression, comparing patients with and without microemboli, and compared the baseline medical therapy at the time of referral at these 2 times.
Sample size calculations show that we needed a total of 398 patients to ascertain a 50% reduction in cardiovascular events in the post-2003 compared with the pre-2003 period, given a cumulative event rate of 20%, power of 80%, and 2-tailed ␣ level of .05.
INTENSIVE THERAPY
By 2003, we had implemented in our clinic a change of treating arteries, rather than simply treating risk factors. Our approach to intensive therapy for accelerated atherosclerosis has previously been described. 24 Therapy was intensified in patients with plaque progression despite routine therapy. This included (1) showing the plaque measurements and plaque images to the patients to impress on them that their plaque was progressing to motivate them to adhere to smoking cessation, exercise, medication, and a Mediterranean diet; (2) increasing the dose of statins to the maximum tolerated dose, regardless of low-density lipoprotein levels (eg, 80 mg of atorvastatin or 40 mg of rosuvastatin); (3) in patients already at their maximum tolerated dose of statins, adding ezetimibe; (4) in those already taking maximum doses of statins and ezetimibe, adding niacin for patients who did not have diabetes or adding fibrates for diabetic patients or those unable to take niacin or slow-release niacin because of flushing; (5) ensuring that the patient was taking an angiotensin-converting enzyme inhibitor, or for those not able to take them because of cough or angioedema, ensuring that they were taking an angiotensinreceptor blocker; (6) optimizing blood pressure control by individualizing therapy according to the renin/aldosterone profile 24 ; and (7) in some patients with insulin resistance (defined by a high fasting insulin level with normal serum glucose level), metformin or pioglitazone was added before the onset of diabetes. . The database was locked as of July 1, 2008 , at which point all patients had at least 1 year of follow-up. Of the total, 7.4% had microemboli, 37.9% were female, 20% were smokers, 18.4% had diabetes, 32% had a history of angina, 11.2% had experienced a myocardial infarction, and 17.2% had intermittent claudication. Mean age was 69.73 years (standard deviation [SD], 8.96 years). Baseline characteristics of this group are presented in Table 1 and Table 2 , divided into those presenting before and after 2003 and with and without microemboli at baseline. The prevalence of microemboli was 12.6% before 2003 and 3.7% since 2003 (P Ͻ.001). After adjustment in binary logistic regression for age, sex, smoking, systolic blood pressure, serum cholesterol, and cholesterol to highdensity lipoprotein cholesterol ratio, the difference remained significant (P = .02).
RESULTS
There
Patients with microemboli had significantly greater carotid stenosis on the index side compared with patients without microemboli: 84.19% vs 76.63% (P = .006). Plasma total homocysteine concentration was significantly higher among patients with microemboli (mean [SD], 16.0 [9.77] vs 10.41 [7. 32] µmol/L). Those with microemboli were significantly more likely to be smokers and to have intermittent claudication; they were also more likely to have intracranial stenosis (Table 1) . Table 3 shows that since 2003, patients were significantly more likely to be taking statins, angiotensinconverting enzyme inhibitors, and clopidogrel at the time of their baseline TCD embolus detection. The medication profiles shown in Table 3 are of medication the patient was taking at the time of referral, after which their therapy was intensified. Table 4 shows that patients with microemboli had significantly more cardiovascular events. Stroke, death, myocardial infarction, or carotid endarterectomy after development of symptoms occurred in 32.4% of patients with microemboli vs 8.6% of those free of microemboli (PϽ.001); this remained significant after adjustment in binary logistic regression for age, sex, smoking, systolic blood pressure, serum cholesterol, and cholesterol to high-density lipoprotein cholesterol ratio (P = .05). Stroke, death, or carotid endarterectomy after development of symptoms occurred in 32.4% of those with microemboli vs 6.5% of those without microemboli (P Ͻ .001); this remained significant in logistic regression as described above (P Ͻ .001). The proportion of patients with cardiovascular events has declined markedly with more intensive medical therapy, from 17.6% of patients enrolled before 2003 to 5.2% since 2003 (P Ͻ .001). This remained significant after adjustment in binary logistic regression as described above (P=.003). Figure 2 shows the Kaplan-Meier survival plots for patients entering the study before and after 2003 and for patients with and without microemboli at baseline. Survival free of stroke, death, or myocardial infarction was significantly better for patients without microemboli and for patients who entered the study after 2003 (log-rank test, PϽ.001 for both analyses).
COMMENT
We found that patients with microemboli remain at a much higher risk, even with more intensive medical therapy, than those without. Table 4 shows that 32.4% of patients with microemboli had a stroke, myocardial infarc- tion, required carotid endarterectomy because their carotid stenosis became symptomatic, or died in the first 2 years; these events occurred in only 8.6% of those without microemboli. However, the 1-year risk of stroke among patients with microemboli has declined from the 15.6% we reported earlier 20 to 10.3%. Risk among patients without microemboli remains low at 1.4%; it should be noted that this is lower than the risk of endarterectomy or stenting. Among patients enrolled since 2003, the rate of events was only 5.2% vs 17.6% of those enrolled between 2000 and 2003, when patients were receiving therapy based on consensus guidelines. These findings confirm that patients with carotid stenosis are at high risk and therefore may require more intensive medical therapy than consensus guidelines recommend and that more intensive medical therapy has markedly reduced not only microemboli, but also cardiovascular events.
Historically, it was thought that patients with ACS would benefit from revascularization if it could be done with a risk of 3% or less. This was based on the Asymptomatic Carotid Artery Surgery study and Asymptomatic Carotid Surgery Trial, 25 which were carried out largely before widespread use of statin drugs (particularly in patients without coronary artery disease). Our findings indicate that with more intensive medical therapy, the stroke risk in ACS and therefore the potential benefit of revascularization have markedly declined.
Hackam and Spence 26 recently calculated that intensive combination therapy could potentially reduce the risk of recurrent stroke by more than 90% in the highest-risk patients. As reported by Rothwell et al, 27 the age-adjusted incidence of stroke in Oxfordshire declined by 40% between 1981 and 2004, probably as the result of more intensive medical therapy, and stroke incidence has also been declining in Ontario, Canada, since the implementation of a provincial network of stroke-prevention clinics. 28 More recently, Rothwell et al 29 have shown that urgent treatment of patients with transient ischemic attacks has markedly reduced the risk of stroke.
The arguments against routine revascularization of patients with ACS have previously been reviewed. 4, 7 Given our finding that intensive medical therapy has reduced the prevalence of microemboli to only 3.7% and markedly reduced cardiovascular events, particularly stroke, we suggest that such intensive medical therapy be regarded as the first line of therapy for patients with ACS.
Given that with intensive medical therapy, the risk of stroke in patients without microemboli is less than the risk of endarterectomy or stenting, we think that revascularization should be considered only for the rare patients with microemboli. Revascularization would only be appropriate in patients without microemboli if it could be done with a risk of less than 1%. Abbreviations: DBP, diastolic blood pressure; HDL, high-density lipoprotein; LDL, low-density lipoprotein; SBP, systolic blood pressure.
SI conversion factors: To convert C-reactive protein to nanomoles per liter, multiply by 9.524; HDL, LDL, and total cholesterol to millimoles per liter, multiply by 0.0259; triglycerides to millimoles per liter, multiply by 0.0113; and vitamin B 12 to picomoles per liter, multiply by 0.7378. a For continuous variables, analysis of variance was used, contrasting patients with and without microemboli. For categorical variables, the Fisher exact test was used (2-sided).
b Sum of the left and right internal carotid artery.
